We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FMC Corp. (FMC) Up 67% YTD: What's Driving the Stock?
Read MoreHide Full Article
Shares of FMC Corporation (FMC - Free Report) have shot up around 67% year to date. The company has also outperformed its industry’s gain of roughly 27% to over the same time frame.
FMC Corp. has a market cap of roughly $12.7 billion and average volume of shares traded in the last three months is around 1,133.9K. The company has an expected long-term earnings per share growth of 11.3%, higher than the industry average of 10.2%.
Let’s take a look into the factors that are driving this Zacks Rank #2 (Buy) stock.
Driving Factors
FMC Corp. is benefiting from its strategic investments, acquisitions and efforts to expand its market position and strengthen its portfolio. Upbeat prospects for the company’s Lithium unit have also provided a boost to its shares.
FMC Corp. is witnessing strong momentum in its Lithium unit. The company is expanding its lithium hydroxide production capacity. It is executing this expansion in three phases. The move is based on the growing demand for electric vehicles.
FMC Corp. has executed its Phase I lithium hydroxide expansion on time and budget, achieving 9,000 metric tons of production run rate in September 2017. The Phase 2 expansion is expected to add another 12,000 metric tons of capacity. The company expects its lithium business to deliver strong earnings growth in 2017.
Acquisitions are also adding strength to the company’s agricultural business. The acquisition of a major portion of DuPont's Crop Protection business has provided a significant growth platform for FMC’s Agricultural Solutions unit. The buyout significantly increases the company’s presence in Asia and Europe.
FMC Corp., in November, raised its earnings view for 2017 and now sees adjusted earnings in the band of $2.59-$2.69 per share for the year (up from the prior view of $2.30 to $2.50 per share), which includes the impact of two months contribution from the DuPont Crop Protection acquisition.
Koppers has an expected long-term earnings growth of 18%. The stock has gained around 25% year to date.
Kronos has an expected long-term earnings growth of 5%. The stock has gained around 115% year to date.
Westlake has an expected earnings growth of 10.6% for the current year. Its shares are up roughly 84% year to date.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
FMC Corp. (FMC) Up 67% YTD: What's Driving the Stock?
Shares of FMC Corporation (FMC - Free Report) have shot up around 67% year to date. The company has also outperformed its industry’s gain of roughly 27% to over the same time frame.
FMC Corp. has a market cap of roughly $12.7 billion and average volume of shares traded in the last three months is around 1,133.9K. The company has an expected long-term earnings per share growth of 11.3%, higher than the industry average of 10.2%.
Let’s take a look into the factors that are driving this Zacks Rank #2 (Buy) stock.
Driving Factors
FMC Corp. is benefiting from its strategic investments, acquisitions and efforts to expand its market position and strengthen its portfolio. Upbeat prospects for the company’s Lithium unit have also provided a boost to its shares.
FMC Corp. is witnessing strong momentum in its Lithium unit. The company is expanding its lithium hydroxide production capacity. It is executing this expansion in three phases. The move is based on the growing demand for electric vehicles.
FMC Corp. has executed its Phase I lithium hydroxide expansion on time and budget, achieving 9,000 metric tons of production run rate in September 2017. The Phase 2 expansion is expected to add another 12,000 metric tons of capacity. The company expects its lithium business to deliver strong earnings growth in 2017.
Acquisitions are also adding strength to the company’s agricultural business. The acquisition of a major portion of DuPont's Crop Protection business has provided a significant growth platform for FMC’s Agricultural Solutions unit. The buyout significantly increases the company’s presence in Asia and Europe.
FMC Corp., in November, raised its earnings view for 2017 and now sees adjusted earnings in the band of $2.59-$2.69 per share for the year (up from the prior view of $2.30 to $2.50 per share), which includes the impact of two months contribution from the DuPont Crop Protection acquisition.
FMC Corporation Price and Consensus
FMC Corporation Price and Consensus | FMC Corporation Quote
Other Stocks to Consider
Other top-ranked companies in the basic materials space include Koppers Holdings Inc. (KOP - Free Report) , Kronos Worldwide, Inc. (KRO - Free Report) and Westlake Chemical Corporation (WLK - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Koppers has an expected long-term earnings growth of 18%. The stock has gained around 25% year to date.
Kronos has an expected long-term earnings growth of 5%. The stock has gained around 115% year to date.
Westlake has an expected earnings growth of 10.6% for the current year. Its shares are up roughly 84% year to date.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>